CXCL16 and type 2 diabetes mellitus: Metformin, a first-line agent for type 2 diabetes treatment, was demonstrated to reduce the gene expression levels of several fibrotic markers, including α-SMA, Collagen1α1, and TGF-β1, which is associated with the reduction of CXCL16 mRNA expression [11].